Cilnidipine

SKU: orb1226543

Description

A dual L- and N-type calcium channel blocker that displays antihypertensive, sympatholytic and neuroprotective activity. Hypertension Approved(In Vitro):Cilnidipine inhibits the L-type current with an IC50 of 100 nM in neurons pretreated with omegaCgTx plus omegaAgTx.The IC50 for Cilnidipine in respect of the N-type current is 200 nM.Cilnidipine dose- and time-dependently inhibits Ba2+ currents in A7r5 cells with the IC50 at 10 nM after 10 min.Cilnidipine dose-dependently inhibits depolarization- and Ca2+-induced contractions of rat aortic rings, with an IC50 of 10 nM at 10 min.The viability of nPC12 cells show no significant change up to 150 μM Cilnidipine, but it decreases slightly in the cells treated with greater than 200 μM Cilnidipine.Cilnidipine (100 μM, 2 hours) treatment increases the expression of p85aPI3K p-Akt, p-GSK-3β, and heat shock transcription factor (HSTF-1), and decreases levels of cytosolic cytochrome c, activated caspase 3, and cleaved PARP.\n(In Vivo):Cilnidipine has potent inhibitory actions on N-type as well as L-type voltage-dependent Ca2+-channel in rat dorsal root ganglion neurons.Administration of Cilnidipine (10 mg/kg) and Nimodipine (10 mg/kg) significantly attenuates the immobilized stress-induced behavioral changes and restored memory deficits along with normalization of the corticosterone levels.Cilnidipine and Nimodipine produce comparable beneficial effects in restoring immobilization stress subjected mice.Oral administration of Cilnidipine (3 mg/kg) markedly lowers both systolic and diastolic blood pressure 1 hr after administration in 2K1C renal hypertensive dogs.

Key Properties

• CAS Number: 132203-70-4
• MW: 492.5204
• Purity: >98% (HPLC)
• Formula: C₂₇H₂₈N₂O₇
• SMILES: O=C(C1=C(C)NC(C)=C(C(OC/C=C/C2=CC=CC=C2)=O)C1C3=CC=CC([N+]([O-])=O)=C3)OCCOC
• Target: Calcium Channel
• Solubility: 10 mM in DMSO

Bioactivity

• In Vivo:
  Cilnidipine has potent inhibitory actions on N-type as well as L-type voltage-dependent Ca2+-channel in rat dorsal root ganglion neurons. Administration of Cilnidipine (10 mg/kg) and Nimodipine (10 mg/kg) significantly attenuates the immobilized stress-induced behavioral changes and restored memory deficits along with normalization of the corticosterone levels. Cilnidipine and Nimodipine produce comparable beneficial effects in restoring immobilization stress subjected mice. Oral administration of Cilnidipine (3 mg/kg) markedly lowers both systolic and diastolic blood pressure 1 hr after administration in 2K1C renal hypertensive dogs. Animal model: Swiss albino mice weighing 25±5 g. Dosage: 5 and 10 mg/kg. Administration: administered i.p. 30 min prior to immobilization stress. Result: Cilnidipine (10 mg/kg, i.p.) and nimodipine (10 mg/kg, i.p.) 30 min prior to subjecting immobilization stress resulted in significant attenuation of immobilization stress-induced decrease in locomotor activity. Administration with Cilnidipine (5 mg/kg, i.p.) and Nimodipine (5 mg/kg, i.p.) did not show any significant effect on the stressed mice. Administration of Cilnidipine (10 mg/kg, i.p.) and Nimodipine (10 mg/kg, i.p.) in the non-stressed mice, and vehicle in the stressed mice did not modulate locomotor activity in a significant manner.
• In Vitro:
  Cilnidipine inhibits the L-type current with an IC50 of 100 nM in neurons pretreated with omegaCgTx plus omegaAgTx. The IC50 for Cilnidipine in respect of the N-type current is 200 nM. Cilnidipine dose- and time-dependently inhibits Ba2+ currents in A7r5 cells with the IC50 at 10 nM after 10 min. Cilnidipine dose-dependently inhibits depolarization- and Ca2+-induced contractions of rat aortic rings, with an IC50 of 10 nM at 10 min. The viability of nPC12 cells show no significant change up to 150 μM Cilnidipine, but it decreases slightly in the cells treated with greater than 200 μM Cilnidipine. Cilnidipine (100 μM, 2 hours) treatment increases the expression of p85aPI3K p-Akt, p-GSK-3β, and heat shock transcription factor (HSTF-1), and decreases levels of cytosolic cytochrome c, activated caspase 3, and cleaved PARP. Cell Viability Assay Cell line: Neuronally differentiated PC12 (nPC12) cells. Concentration: 0, 1, 5, 10, 25, 50, 100, 150, and 200 μM. Incubation time: Treated for 2 hours; cell viability was measured after 24 hours. Result: Cell viability was not affected by low concentrations up to 150 μM, but it was slightly decreased at 200 μM. Western blot analysis. Cell line: nPC12 cells. Concentration: 100 μM. Incubation time: 2 hours. Result: Increased the IRs of p58a PI3K, p-Akt, p-GSK-3β, and HSTF-1 and decreased the Immunoreactivities (IRs) of cytosolic cytochrome c, activated caspase 3 (17 kDa), and cleaved PARP (85 kDa).

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

FRC-8653

Quick Database Links

Gene Symbol

Calcium Channel